REAL-WORLD BORTEZOMIB USAGE PATTERNS AMONG PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Author(s): ,
Geoffrey Calkins
Affiliations:
Flatiron Health,New York,United States
,
Jeremy Kohansimeh
Affiliations:
Flatiron Health,New York,United States
,
Arun Krishna
Affiliations:
Novartis Pharmaceuticals,East Hanover,United States
,
Robert J. Green
Affiliations:
Flatiron Health,New York,United States
,
Melissa Curtis
Affiliations:
Flatiron Health,New York,United States
,
Frederik P. Lindberg
Affiliations:
Flatiron Health,New York,United States
,
Ann Jaskiw
Affiliations:
Flatiron Health,New York,United States
,
Katherine Larrabee
Affiliations:
Flatiron Health,New York,United States
,
May Terry
Affiliations:
Flatiron Health,New York,United States
,
Ross N. Feinstein
Affiliations:
Flatiron Health,New York,United States
,
Lesley Plotkin
Affiliations:
Flatiron Health,New York,United States
,
M. Lou Palladino
Affiliations:
Flatiron Health,New York,United States
Leonardo Viana Nicacio
Affiliations:
Flatiron Health,New York,United States
EHA Learning Center. Krishna A. Jun 12, 2015; 102812
Arun Krishna
Arun Krishna

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.


Abstract
Discussion Forum (0)
Rate & Comment (0)
Abstract: PB1881

Type: Publication Only

Background

The 2012 FDA approval of subcutaneous (SC) bortezomib (BTZ) was based on non-inferior efficacy and reduced toxicity vs intravenous (IV) administration of BTZ. While differences in BTZ toxicity are attributed to route, dose, schedule, and duration, little is known about BTZ use in recent real-world practice in the US. 



Aims
This study aimed to examine the real-world use of bortezomib in relapsed/refractory multiple myeloma patients in the US.

Methods

Patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM) were selected from a longitudinal, nationally-representative electronic medical record (EMR) database (Flatiron Health). MM diagnoses were confirmed by physician (MD) notes. Pts were required to have disease progression following 1st line of therapy (LOT), ≥ 1 visit after 2010, and ≥ 3 months follow-up post-progression. Pt-level data were integrated from structured and unstructured EMR sources: transplant status abstracted from MD notes and IV/SC administration data merged with oral data from MD notes. We evaluated BTZ usage among these pts with R/R MM.



Results
We identified 607 pts with R/R MM; among these pts, 542 (89%) received BTZ. There were 830 LOTs containing BTZ. Initiation with SC vs IV BTZ increased over time (2011: 13% SC; 2012: 64% SC; 2013: 76% SC; 2014: 71% SC). Among BTZ initiations after 2012, 34% of those starting IV BTZ later switched to SC (7% of SC BTZ initiations later switched to IV). Across all BTZ initiations, 47% started at a schedule of > once per week (1×/wk); the rate was higher in earlier LOTs and transplant recipients (Table 1). BTZ initiations starting at 1x/wk were associated with longer duration (4.9 vs. 4.0 months, p=0.02), fewer dose reductions (26% vs. 40%, p<0.01) and similar cumulative total dose (median of 20.8 vs. 22.3 mg/m2, p=0.24) than BTZ initiations starting at >1x/wk.

Summary
To our knowledge, this is the first real-world study evaluating evolving patterns of BTZ use in pts with R/R MM in the US. There was increased SC administration after 2012, longer duration of treatment among those starting at 1x/wk, and fewer dose reductions among those starting at 1x/wk; all which may be associated with toxicity management. 



Session topic: Publication Only
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings